January 28, 2021

Contents

Clinical Profile: Problem Additions

The following items are available for documentation in **Problems** and appear on the **Charge Capture Report** (CCR). *Additional ICD10 codes may display to present the surrounding nodes.*

Problem	ICD10 Code Choice(s)*
Acute pain	G43.809 - Other migraine, not intractable, without status migrainosus G43.819 - Other migraine, intractable, without status migrainosus G44.319 - Acute post-traumatic headache, not intractable G89.0 - Central pain syndrome G89.11 - Acute pain due to trauma G89.12 - Acute post-thoracotomy pain G89.18 - Other acute postprocedural pain G89.21 - Chronic pain due to trauma G89.22 - Chronic post-thoracotomy pain G89.28 - Other chronic postprocedural pain G89.29 - Other chronic pain G89.3 - Neoplasm related pain (acute) (chronic) G89.4 - Chronic pain syndrome M25.561 - Pain in right knee M25.562 - Pain in left knee M25.569 - Pain in unspecified knee M25.571 - Pain in right ankle and joints of right foot M25.572 - Pain in left ankle and joints of left foot M25.579 - Pain in unspecified ankle and joints of unspecified foot M54.40 - Lumbago with sciatica, unspecified side M54.41 - Lumbago with sciatica, right side M54.42 - Lumbago with sciatica, left side M54.5 - Low back pain M54.6 - Pain in thoracic spine R07.9 - Chest pain, unspecified R10.0 - Acute abdomen R10.2 - Pelvic and perineal pain R10.9 - Unspecified abdominal pain R51.0 - Headache with orthostatic component, not elsewhere classified R51.9 - Headache, unspecified R52 - Pain, unspecified
Sore throat	J02.0 - Streptococcal pharyngitis J02.8 - Acute pharyngitis due to other specified organisms J02.9 - Acute pharyngitis, unspecified J31.0 - Chronic rhinitis J31.1 - Chronic nasopharyngitis J31.2 - Chronic pharyngitis R07.0 - Pain in throat

Lab Analyte and Panel Additions and Updates

- % Infected cells seen
- ABL1 kinase domain mutation analysis - ABL1 kinase domain mutations
- ABL1 kinase domain mutation analysis - mutation(s)
- AChR ganglionic neuronal Ab, S
- AGNA-1, S
- AGNA-1, serum
- AKT1 mutation analysis
- AKT1 mutation analysis - mutations(s)
- AMPA-R Ab CBA, serum
- Amphiphysin Ab, serum
- ANNA-1, S
- ANNA-1, serum
- ANNA-2, serum
- ANNA-3, serum
- Antibody screen cold screen, qual
- ARID1A mutation analysis
- ARID1A mutation analysis - mutations(s)
- ASXL1 mutation analysis - ASXL1 mutation analysis
- ASXL1 mutation analysis - mutation(s) detected
- ATRX mutation analysis - ATRX mutation analysis
- ATRX mutation analysis - mutation(s)
- BCOR mutation analysis - BCOR mutation analysis
- BCOR mutation analysis - mutation(s)
- BCORL1 mutation analysis - BCORL1 mutation analysis
- BCORL1 mutation analysis - mutation(s)
- BRAF mutation analysis - BRAF mutation
- BRAF mutation analysis - mutation(s)
- BRAF mutation analysis, BRAF mutation
- BRAF mutation analysis, mutation(s)
- Breast cancer prognostic intensity of stain
- Breast cancer prognostic methodology
- Breast Cancer prognostic profile
- Breast cancer prognostic reference range
- CALR mutation analysis - CALR mutation analysis
- CALR mutation analysis - mutation
- Calreticulin (CALR) mutation analysis - CALR mutation(s)
- Calreticulin (CALR) mutation analysis - CALR percentage
- Calreticulin (CALR) mutation analysis - Calreticulin (CALR) mutation
- CASPR2 IgG CBA, serum
- CBL mutation analysis - CBL mutation analysis
- CBL mutation analysis - mutation(s) detected
- CBL mutation analysis, CBL mutation analysis
- CBLB mutation analysis - CBLB mutation analysis
- CBLB mutation analysis - mutation(s)
- CBLC mutation analysis - CBLC mutation analysis
- CBLC mutation analysis - mutation(s)
- CDH1 mutation analysis
- CDH1 mutation analysis - mutation(s)
- CDKN2A mutation analysis
- CDKN2A mutation analysis - CDKN2A mutation analysis
- CDKN2A mutation analysis - mutation(s)
- CEBPA mutation analysis - CEBPA mutation
- CEBPA mutation analysis - mutation(s)
- CEBPA mutation analysis - SNP rs34529039
- Choriogonadotropin, mIU/L
- Chromogranin A
- Chromogranin A Re-Baseline panel
- Chromogranin A, intact/fragments
- Chromogranin A, serum, ng/mL
- Cold agglutinin screen panel
- COVID-19 screen panel
- COVID-19 screen, qual
- CRMP-5 IgG, serum
- CRMP-5-IgG, S
- CSF3R mutation analysis - CSF3R mutation
- CSF3R mutation analysis - mutation(s)
- CUX1 mutation analysis - CUX1 mutation analysis
- CUX1 mutation analysis - mutation(s)
- DDX41 mutation analysis - DDX41 mutation analysis
- DDX41 mutation analysis - mutation(s)

- DNMT3A mutation analysis - DNMT3A mutation
- DNMT3A mutation analysis - mutation(s)
- DPPX Ab IFA, serum
- EGFR mutation analysis by Sanger - EGFR Exon 18
- EGFR mutation analysis by Sanger - EGFR Exon 19
- EGFR mutation analysis by Sanger - EGFR Exon 20 other mutations
- EGFR mutation analysis by Sanger - EGFR Exon 20 T790M
- EGFR mutation analysis by Sanger - EGFR Exon 21
- EGFR mutation analysis by Sanger - overall result
- Encephalopathy autoimmune evaluation panel
- Encephalopathy autoimmune interpretation
- ERBB2 mutation analysis
- ERBB2 mutation analysis - mutation(s)
- ERBB3 mutation analysis
- ERBB3 mutation analysis - mutation(s)
- ERBB4 mutation analysis
- ERBB4 mutation analysis - mutation(s)
- Estrogen receptor assay (ERA) measurement
- Estrogen receptor results
- ETNK1 mutation analysis
- ETNK1 mutation analysis - mutation(s)
- ETV6 mutation analysis - ETV6 mutation
- ETV6 mutation analysis - mutation(s)
- EZH2 mutation analysis - EZH2 mutation analysis
- EZH2 mutation analysis - mutation(s) detected
- FBXW7 mutation analysis - FBXW7 mutation analysis
- FBXW7 mutation analysis, mutation(s)
- FGFR1 mutation analysis
- FGFR1 mutation analysis - mutation(s)
- FGFR2 mutation analysis
- FGFR2 mutation analysis - mutation(s)
- FGFR3 mutation analysis
- FGFR3 mutation analysis - mutation(s)
- FLT3 mutation analysis - FLT3 mutation
- FLT3 mutation analysis - FLT3-ITD Insertion Size (bp)
- FLT3 mutation analysis, FLT3 mutation
- FLT3 mutation analysis, FLT3-ITD insertion size (bp)
- GABA-B-R Ab CBA, serum
- GAD65 Ab serum assay, nmol/L
- GATA1 mutation analysis
- GATA1 mutation analysis - mutation(s)
- GATA2 mutation analysis - GATA2 mutation analysis
- GATA2 mutation analysis - mutation(s)
- Genetics Method
- Genetics Specimen ID
- Genetics Specimen source
- GFAP IFA, serum
- GNAS mutation analysis - GNAS mutation
- GNAS mutation analysis, mutation(s)
- GNB1 mutation analysis
- GNB1 mutation analysis - mutation(s)
- HER2 copies/cell
- HER2 ratio, FISH
- HER2, qual, IHC
- HER2/NEU interpretation
- HRAS mutation analysis - HRAS mutation
- HRAS mutation analysis - mutation(s)
- HRAS mutation analysis, HRAS mutation
- HRAS mutation analysis, mutation(s)
- Human chorionic gonadotropin (hCG) panel
- IDH1/IDH2 mutation analysis - IDH1 mutation
- IDH1/IDH2 mutation analysis - IDH1/IDH2 mutation
- IDH1/IDH2 mutation analysis - IDH2 mutation
- IDH1/IDH2 mutation analysis, IDH1 mutation
- IDH1/IDH2 mutation analysis, IDH2 mutation
- IGF-1 LC/MS, IGFBP-3 growth panel
- IGF-1, LC/MS, S
- IGFBP-3, S
- IgLON5 IFA, serum
- IKZF1 mutation analysis
- IKZF1 mutation analysis - mutation(s)
- Interpretive comments
- JAK2 Exon 12-14 mutation analysis - JAK2, EXON 12-14 mutation
- JAK2 Exon 12-14 mutation analysis - mutation(s)
- JAK2 Exon 12-14 mutation analysis, mutation(s)
- JAK2 V617F mutation analysis - Qualitative - JAK2 V617F mutation

- JAK2 V617F mutation analysis - Qualitative - mutation(s)
- JAK3 mutation analysis, JAK3 mutation analysis
- JAK3 mutation analysis, mutation(s)
- KDM6A mutation analysis
- KDM6A mutation analysis - mutation(s)
- Ki-67, %
- KIT (c-KIT) mutation analysis
- KIT (c-KIT) mutation analysis - c-KIT Exon 11
- KIT (c-KIT) mutation analysis - c-KIT Exon 17
- KIT (c-KIT) mutation analysis - c-KIT Exon 8
- KIT (c-KIT) mutation analysis - c-KIT Exon 9
- KIT (c-KIT) mutation analysis - KIT (c-Kit) mutation
- KIT (c-KIT) mutation analysis, c-KIT exon 11
- KIT (c-KIT) mutation analysis, c-KIT exon 17
- KIT (c-KIT) mutation analysis, c-KIT exon 8
- KIT (c-KIT) mutation analysis, c-KIT exon 9
- KRAS mutation analysis
- KRAS mutation analysis - KRAS mutation
- KRAS mutation analysis - mutation(s)
- KRAS mutation analysis, KRAS mutation
- KRAS mutation analysis, mutation(s)
- Lab result note
- LGI1 IgG CBA, serum
- Malaria antigen
- Malaria antigen panel
- Malaria thick smear panel
- Malaria thin smear
- Malaria thin smear panel
- MET (c-MET) mutation analysis
- MET (c-MET) mutation analysis - mutation(s)
- MET FISH
- mGluR1 Ab IFA, serum
- MLH1 sequencing - MLH1 sequencing
- MLH1 sequencing result
- MLL mutation analysis - MLL mutation analysis
- MLL mutation analysis, mutation(s)
- MOG FACS titer, serum
- MPL mutation analysis - MPL mutation
- MPL mutation analysis - MPL S505 mutation
- MPL mutation analysis - MPL W515 mutation
- MSH2 sequencing
- MSH2 sequencing result
- MSH6 sequencing - MSH6 sequencing
- MSH6 sequencing result
- MYD88 mutation analysis - mutation(s) detected
- MYD88 mutation analysis - MYD88 mutation(s)
- Myelin oligodendrocyte glycoprotein (MOG-IgG1) fluorescence-activated cell sorting (FACS) assay, serum
- NeoLAB myeloid disorders PDF
- NeoLAB myeloid disorders profile comments
- NeoLAB(TM) myeloid disorders profile
- NeoTYPE Gastric tumor comments
- NeoTYPE Gastric tumor PDF
- NeoTYPE(TM) Gastric tumor profile
- NeoType(TM) MDS/CMML comments
- NeoTYPE(TM) MDS/CMML Profile
- Neuronal (V-G) K+ channel Ab, S
- NF1 mutation analysis - mutation(s)
- NF1 mutation analysis - NF1 mutation analysis
- NF1 mutation analysis, mutation(s)
- NIF IFA, serum
- NMDA-R Ab CBA, seum
- NOTCH1 mutation analysis
- NOTCH1 mutation analysis - mutation(s) detected
- NOTCH1 mutation analysis - NOTCH1 mutation analysis
- NOTCH1 mutation analysis, mutation(s) detected
- NPM1 mutation analysis - NPM1 mutation
- NRAS mutation analysis - mutation(s)
- NRAS mutation analysis - NRAS mutation
- NRAS mutation analysis, mutation(s)
- NRAS mutation analysis, NRAS mutation
- N-Type calcium channel Ab
- P/Q-Type calcium channel Ab
- Pan-TRK
- Pan-TRK marker result
- Pathology/Cytology Specimen ID
- Pathology/Cytology Specimen source
- Paval panel (paraneoplastic autoantibody evaluation)
- PCA-1, S

- PCA-1, serum
- PCA-2, S
- PCA-2, serum
- PCA-Tr, S
- PCA-Tr, serum
- PDGFRa mutation analysis - mutation(s) detected
- PDGFRa mutation analysis - PDGFRa mutation(s)
- PD-L1 22C3 FDA (Keytruda) for Gastric/GEA combined positive score
- PD-L1 22C3 FDA (Keytruda) for Gastric/GEA result
- PHF6 mutation analysis - mutation(s)
- PHF6 mutation analysis - PHF6 mutation analysis
- PIK3CA LDT mutation analysis by sequencing
- PIK3CA LDT mutation analysis by sequencing - PIK3CA Exon 1
- PIK3CA LDT mutation analysis by sequencing - PIK3CA Exon 20
- PIK3CA LDT mutation analysis by sequencing - PIK3CA Exon 9
- PML mutation analysis - mutation(s) detected
- PML mutation analysis - PML mutation analysis
- PMS2 sequencing - PMS2 sequencing
- PMS2 sequencing result
- PPM1D mutation analysis - mutation(s) detected
- PPM1D mutation analysis - PPM1D mutation(s)
- PREX2 mutation analysis
- PREX2 mutation analysis - mutation(s) detected
- Progesterone receptor assay measurement
- Progesterone receptor results
- PTEN FISH
- PTEN FISH note
- PTEN mutation analysis - mutation(s) detected
- PTEN mutation analysis - PTEN mutation analysis
- PTPN11 mutation analysis - mutation(s) detected
- PTPN11 mutation analysis - PTPN11 mutation analysis
- RAD21 mutation analysis - mutation(s)
- RAD21 mutation analysis - RAD21 mutation analysis
- Recombx CV2 autoantibody comments
- Recombx CV2 autoantibody interpretation
- Recombx CV2 autoantibody methods
- Recombx CV2 autoantibody panel
- Recombx CV2 autoantibody references
- Recombx CV2 autoantibody techincal results
- Reflex added
- RNF43 mutation analysis
- RNF43 mutation analysis - mutation(s) detected
- RUNX1 mutation analysis - mutation(s) detected
- RUNX1 mutation analysis - RUNX1 mutation analysis
- SETBP1 mutation analysis - mutation(s)
- SETBP1 mutation analysis - SETBP1 mutation
- SF3B1 mutation analysis - mutation(s)
- SF3B1 mutation analysis - SF3B1 mutation
- SH2B3 mutation analysis - mutation(s)
- SH2B3 mutation analysis - SH2B3 mutation analysis
- SMAD4 mutation analysis
- SMAD4 mutation analysis - mutation(s)
- SMC1A mutation analysis - mutation(s)
- SMC1A mutation analysis - SMC1A mutation analysis
- SMC3 mutation analysis - mutation(s)
- SMC3 mutation analysis - SMC3 mutation analysis
- SMO mutation analysis
- SMO mutation analysis - mutation(s)
- SRC mutation analysis
- SRC mutation analysis - mutation(s)
- SRSF2 mutation analysis - mutation(s) detected
- SRSF2 mutation analysis - SRSF2 mutation analysis
- STAG2 mutation analysis - mutation(s)
- STAG2 mutation analysis - STAG2 mutation analysis
- STAT3 mutation analysis - mutation(s)
- STAT3 mutation analysis - STAT3
- STAT5B mutation analysis - mutation(s)
- STAT5B mutation analysis - STAT5B mutation analysis
- Striational (striated muscle) Ab, S
- TERT gene promoter mutation analysis by NGS

- TERT gene promoter mutation analysis by NGS - mutation(s)
- TET2 mutation analysis - mutation(s) detected
- TET2 mutation analysis - TET2 mutation analysis
- TGFBR2 mutation analysis
- TGFBR2 mutation analysis - mutation(s) detected
- TP53 mutation analysis
- TP53 mutation analysis - TP53 Exon 4
- TP53 mutation analysis - TP53 Exon 5
- TP53 mutation analysis - TP53 Exon 6
- TP53 mutation analysis - TP53 Exon 7
- TP53 mutation analysis - TP53 Exon 8
- TP53 mutation analysis - TP53 Exon 9
- TP53 mutation analysis - TP53 mutation
- TP53 mutation analysis, TP53 Exon 4
- TP53 Mutation Analysis, TP53 Exon 5
- TP53 mutation analysis, TP53 Exon 6
- TP53 Mutation Analysis, TP53 Exon 7
- TP53 Mutation Analysis, TP53 Exon 8
- TP53 Mutation Analysis, TP53 Exon 9
- U2AF1 mutation analysis - mutation(s) detected
- U2AF1 mutation analysis - U2AF1 mutation analysis
- Wilson disease interpretation
- Wilson disease released
- Wilson disease result
- Wilson disease result summary
- Wilson disease specimen
- Wilson disease, full gene analysis panel
- WT1 mutation analysis - mutation(s)
- WT1 mutation analysis - SNP rs16754
- WT1 mutation analysis - WT1 mutation
- ZRSR2 mutation analysis - mutation(s) detected
- ZRSR2 mutation analysis - ZRSR2 mutation analysis
- Z-score

Medication

Additions

- ABT-869 invest or placebo Oral
- Ad-RTS-hIL-12 invest IV
- AP23573 invest oral
- ARV-110 invest Oral
- ASG-5ME invest IV
- AST-008 invest Intratumoral
- AST-008 invest Subcutaneous
- AST-008 invest Subcutaneous (Cavrotolimod invest)
- Cavatak invest Intratumoral
- Cavatak invest Intratumoral (CVA21 invest)
- GEN3009 invest IV
- ICP-192 invest Oral
- CC-223 invest Oral
- CMX001 invest Oral
- CT-011 invest IV
- ERAS-601 invest Oral
- G-202 invest IV
- gE/AS01b invest IV
- JTX-4014 invest IV
- KB-0742 invest Oral
- LCL161 invest Oral
- LOXO-305 invest Oral
- LY2495655 invest or placebo IV
- LY355703 invest IV
- Pimasertib invest Oral
- Proxalutamide (GT0918) invest Oral
- Proxalutamide (GT0918) invest oral
- Relugolix Oral
- Romosozumab-aqqg Subcutaneous
- SAR245408 invest Oral
- SAR245409 invest Oral
- SGI-110 invest IV
- SGT-53 invest IV
- Tislelizumab invest IV
- TTX-080 invest IV
- XL102 invest Oral

Updates

- AB122 invest IV – Synonym: AB122 (zimberelimab) invest is now available.
- AB928 invest Oral – Synonym: AB928 (etrumadenant) invest is now available.
- AMB 510 invest Oral – Synonym: AMG 510 (Sotorasib) invest is now available.
- Crizotinib Oral – the following quick sigs are now available:
  - 400 mg orally daily
  - 500 mg orally daily
  - 500 orally 2 time per day, 500 mg orally 2 time per day; swallow whole, do not chewbreakdissolve/open
- Fam-Trastuzumab Deruxtecn-nxki IV (Enhertu) – the following quick sigs are now available:
  - 4.4 mg/kg intravenously piggyback once
  - 5.4 mg/kg intravenously piggyback once
- Melflufen invest IV - Updated the form from 50 mL solution to 20 mg solution
- Pertuzumab-Trastuzumab-Hy-zzxf Subcutaneous 1200 mg-600 mg-30,000 unit/15 mL
  - Instructions now default to: LOADING DOSE: 15 mL = 1200 mg pertuzumab-600 mg trastuzumab-30,000 units hyaluronidase. Administer initial injection (LOADING DOSE) over 8 minutes. Do NOT further dilute. Compatible with stainless steel, polypropylene, polycarbonate, polyethylene, polyurethane, polyvinyl chloride or fluorinated ethylene polypropylene. Administer using 25 to 27-gauge hypodermic injection needle. The subcutaneous injection site should be alternated between the left and right thigh. New injections should be given at least 1 inch (2.5 cm) from the previous site on healthy skin and never into areas where the skin is red, bruised, tender, or hard. Do not split the dose between two syringes or between two sites of administration. Other medications for subcutaneous administration should be injected at different sites. Observe patients for a minimum of 30 minutes after initial dose of PHESGO and 15 minutes after each maintenance dose of PHESGO for signs of hypersensitivity symptoms or administration-related reactions. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use. **For Subcutaneous Administration Only** NOTE: This is Phesgo.
  - Maximum Single Dose values include 1200 mg and 15 mL
- Pertuzumab-Trastuzumab-Hy-zzxf Subcutaneous 600 mg-600 mg-20,000 unit/10 mL
  - Instructions now default to: MAINTENANCE DOSE: 10 mL = 600 mg pertuzumab-600 mg trastuzumab-20,000 units hyaluronidase. Administer subsequent or maintenance dose injections (MAINTENANCE DOSE) over 5 minutes. Do NOT further dilute. Compatible with stainless steel, polypropylene, polycarbonate, polyethylene, polyurethane, polyvinyl chloride or fluorinated ethylene polypropylene. Administer using 25 to 27-gauge hypodermic injection needle. The subcutaneous injection site should be alternated between the left and right thigh. New injections should be given at least 1 inch (2.5 cm) from the previous site on healthy skin and never into areas where the skin is red, bruised, tender, or hard. Do not split the dose between two syringes or between two sites of administration. Other medications for subcutaneous administration should be injected at different sites. Observe patients for a minimum of 30 minutes after initial dose of PHESGO and 15 minutes after each maintenance dose of PHESGO for signs of hypersensitivity symptoms or administration-related reactions. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use. **For Subcutaneous Administration Only** NOTE: This is Phesgo.
  - Maximum Single Dose values include 1200 mg and 10 mL

- Surufatinib invest (HMPL-012)
  - Medication name is now Surufatinib invest (HMPL-012) Oral, updated from Surufatinib invest Oral.
  - Dispensables 250 mg capsule and 300 mg capsule are now available

Drug Name	Removed Maximum Single Dose	New Maximum Single Dose	Rounding Rule
Belatacept IV	10 mg/kg		
Cabazitaxel IV	25 mg/m2		
Cladribine IV	0.7 mg/kg (VIA CONTINUOUS INFUSION); 0.14 mg/kg (INTRAVENOUS, INTRAVENOUSLY)		
Cladribine Subcutaneous	0.7 mg/kg; 105 mg	21 mg	
Cladribine Oral			10 mg
Crizanlizumab-tmca IV	5 mg/kg		
Cytarabine (PF) Subcutaneous		375 mg	
Cytarabine Subcutaneous		375 mg	
Cytarabine (PF) IV		3500 mg (VIA CONTINUOUS INFUSION); 7500 mg (INTRAVENOUS, INTRAVENOUSLY)	
Dactinomycin IV	1250 mcg/m2		
Darbepoetin Alfa in Polysorbate IV	0.75 mcg/kg		
Epoetin alfa-epbx Subcutaneous		90000 units	1000 units
Epoetin alfa-epbx IV		90000 units	1000 units
Etoposide IV	300 mg (INTRAVENOUS, INTRAVENOUSLY); 72 mg/m2 (VIA CONTINUOUS INFUSION)	500 mg (INTRAVENOUS, INTRAVENOUSLY)	
Fam-Trastuzumab Deruxtecn-nxki IV	810 mg	960 mg	
Gemcitabine IV		3130 mg	
Gemtuzumab IV	6 mg/m2		
Givosiran Subcutaneous	2.5 mg/kg		
Inotuzumab Ozogamicin IV	0.8 mg/m2		
Ixabepilone IV	40 mg/m2		
Levoleucovorin IV	250 mg/m2		
Luspatercept-aamt Subcutaneous	1.75 mg/kg		
Melphalan IV	30 mg/m2		
Melphalan Oral	0.25 mg/kg; 9 mg/m2		
Mesna Oral	1200 mg/m2; 3000 mg	3200 mg	
Procarbazine Oral	100 mg/m2		
Selumetinib-Vitamin E TPGS Oral	25 mg/m2		
Tagraxofusp-erzs IV	12 mcg/kg		

Drug Name	Removed Maximum Single Dose	New Maximum Single Dose	Rounding Rule
Thioguanine Oral	2 mg/kg		
Venetoclax Oral	600 mg	800 mg	
Venetoclax Oral Starter Pack 10 mg-50 mg-100 mg	600 mg	800 mg	

Regimens

Regimens containing Phesgo have maintained the current dose in mL to minimize risk for dosing errors that may occur with assigning dose based on a single therapeutic component or sum of therapeutic components.

Additions

The following regimens are now available for ordering in the Regimen Library.

- Atezolizumab + Abraxane D1,8 Q14D fb Atezolizumab + Doxorubicin + Cyclophosphamide (AC) Q14D Dose Dense
- Atezolizumab Q21D (Adjuvant Breast)
- Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Nivolumab Q21D
- Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Pembrolizumab Q21D
- Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Trastuzumab IV BIOSIMILAR Q21D
- Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Trastuzumab IV Q21D
- Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) Q21D (Ovarian)
- Fam-Trastuzumab Deruxtecan-nxki Q21D (Colon, Rectal, Gastric, NSCLC)
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Nivolumab Q14D
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) (Q14D) + Pembrolizumab (Q21D) Q42D
- Fluorouracil CIV D1-5 + Cisplatin + Pembrolizumab Q21D
- Ixazomib D1,8,15 + Cyclophosphamide PO D1,8,15 + Dexamethasone D1,8,15,22 Q28D
- Ixazomib D1,8,15 + Cyclophosphamide PO D1,8,15 + Dexamethasone D1,8,15,22 Q28D (Ixazomib Continuation)
- Nivolumab D1,15 fb D1 Q28D (Adjuvant Esophageal)
- Relugolix Q30D
- Selinexor D1,8,15,22,29 + Bortezomib D1,8,15,22 + Dexamethasone Q35D
- Trifluridine/Tipiracil D1-5, D8-12 + Bevacizumab BIOSIMILAR D1,15 Q28D
- Trifluridine/Tipiracil D1-5, D8-12 + Bevacizumab D1,15 Q28D
- Venetoclax + Dexamethasone D1,8,15 Q21D

Updates

The Pegfilgrastim BIOSIMILAR regimen is no longer available for ordering in the Regimen Library.

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- All Problems
- Anemia, Hemolytic
- Autoimmune (Parent)
- Bladder Cancer
- Breast Cancer
- Colon Cancer
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gastric Cancer
- Immune Thrombocytopenia Purpura (ITP)
- Leukemia, Chronic Lymphocytic (CLL)
- Lung Cancer, Non-Small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Multiple Myeloma (MM)
- Ovarian and Primary Peritoneal Cancer
- Prostate Cancer
- Rectal Cancer
- Waldenstrom's Macroglobulinemia

Research

Regimen Additions

To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.

Updates

The USOR Clinical Trials listed in the table below are updated:

	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
USOR 18013	X	X	X	
USOR 18168	X			
USOR 18234	X		X	
USOR 19081	X			
USOR 19105	X			

	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
USOR 19187	X	X		
USOR 19192	X	X		
USOR 19225	X	X	X	
USOR 19245	X		X	
USOR 20343	X		X	

Billing: HCPCS Code Updates

Medication	HCPSC Code
Albuterol HFA Inhaler 90 mcg/actuation	J7613 per 1 puff
COVID-19 Vaccine, AZD-1222 (AstraZeneca) (PF) IM (Unapproved)	91302 per 0.5 mL
Lurbinectedin IV	J9223 per 0.1 mg
Pantoprazole IV	J3490 per 40 mg
Pertuzumab-Trastuzumab-Hy-zzxf Subcutaneous 1200 mg-600 mg-30,000 unit/15 mL	J9316 per 10 mg J9316 per 0.125 mL
Pertuzumab-Trastuzumab-Hy-zzxf Subcutaneous 600 mg-600 mg-20,000 unit/10 mL	J9316 per 10 mg J9316 per 0.167 mL
Relugolix Oral (Orgovyx)	J8999 per 120 mg